Reid Thompson, M.D., Ph.D. is an assistant professor of radiation medicine and a member of the Knight Cancer Institute’s Computational Biology Program. He received his medical and doctorate degrees from the Albert Einstein College of Medicine and trained at the University of Pennsylvania. He also holds degrees in genetics and biophysical chemistry.
Immunotherapy has opened a new frontier in cancer treatment and has improved survival for many patients with metastatic melanoma and other aggressive cancers. The field of immunotherapy is exciting and fast-evolving, however there remain a number of critical questions regarding predictors of immunotherapy response and treatment-related toxicity. The Thompson Lab is actively engaged in this field broadly, and focused specifically on cancer neoepitope prediction and genomic correlates of immunotherapy response and toxicity. The lab has multiple active projects ongoing, from development of novel software tools and algorithms to analysis of large immunotherapy datasets to clinical informatics based investigations of cancer outcomes.
Lung cancer screening of high-risk individuals has been shown to improve survival in the population, and can lead to earlier diagnosis, earlier stage migration, and more effective treatment for the disease. However, there are many outstanding issues and opportunities for improving lung cancer outcomes. In conjunction with The Knight Cancer Institute's, Center for Cancer Early Detection Advanced Research (CEDAR), the Thompson Lab is investigating biomarkers for early detection of lung cancer and lung cancer outcomes prediction.
Dr. Thompson serves as a co-leader of the Portland VA's Clinical Data Science Research Group (CDSRG). Within the scope of the CDSRG, the Thompson Lab is actively investigating patterns of cancer care and long-term patient outcomes within the VA, particularly as related to radiotherapy.
About Thompson Lab
Julianne David, Ph.D. student
Mary Wood, Research Associate
June 25, 2021
Reid Thompson, M.D., Ph.D. has been awarded a Medical Research Foundation: Spring 2021 New Investigator Award for his proposal "The influence of human leukocyte antigen variability on COVID-19 disease severity".
June 8, 2020
Reid Thompson, M.D., Ph.D. has been awarded the 2020 ASTRO-MRA (Melanoma Research Alliance) Young Investigator Award for his proposal Ablative Radiotherapy as Consolidation for Oligoprogressive Melanoma. This award will further the translational research platform of the already strong Melanoma Research Program of the Knight Cancer Institute.
April 13, 2018
Reid Thompson, M.D., Ph.D., assistant professor, presented webinar on Artificial Intelligence in Radiation Oncology
April 12, 2018
Artificial Intelligence in Radiation Oncology, ACR Data Science Institute podcast featuring Dr. Reid Thompson
March 7, 2018
Reid Thompson, M.D., Ph.D. participated in 60th Annual ASTRO panel, "Current Applications & Future Directions"
May 6, 2017
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. Gordon NS, Baxter LA, Goel A, Arnold R, Kaur B, Liu W, Pirrie SJ, Hussain S, Viney R, Ford D, Zarkar A, Wood MA, Mitin T, Thompson RF, James ND, Ward DG, Bryan RT.BJU Int. 2021 Sep 7. doi: 10.1111/bju.15589.
pepsickle rapidly and accurately predicts proteasomal cleavage sites for improved neoantigen identification. Weeder BR, Wood MA, Li E, Nellore A, Thompson RF.Bioinformatics. 2021 Sep 3:btab628. doi: 10.1093/bioinformatics/btab628.
Thromboembolic risk in patients with lung cancer receiving systemic therapy. Madison CJ, Melson RA, Conlin MJ, Gundle KR, Thompson RF, Calverley DC.Br J Haematol. 2021 Jul;194(1):179-190. doi: 10.1111/bjh.17476
Human methylome variation across Infinium 450K data on the Gene Expression Omnibus. Maden SK, Thompson RF, Hansen KD, Nellore A.NAR Genom Bioinform. 2021 Apr 22;3(2):lqab025. doi: 10.1093/nargab/lqab025
Radiomic biomarkers of tumor immune biology and immunotherapy response. Wang JH, Wahid KA, van Dijk LV, Farahani K, Thompson RF, Fuller CD. Clinical & Translational Radiation Oncology (2021). :https://doi.org/10.1016/j.ctro.2021.03.006
Utility of the Current Procedural Terminology Codes for Prophylactic Stabilization for Defining Metastatic Femur Disease. Hanna SM, Ramsey DC, Doung YC, Hayden JB, Thompson RF, Summers AR, Gundle KR.J Am Acad Orthop Surg Glob Res Rev. 2020 Dec 18;4(12):e20.00167. doi: 10.5435/JAAOSGlobal-D-20-00167.
Meeting the Challenge of Scientific Dissemination in the Era of COVID-19: Toward a Modular Approach to Knowledge-Sharing for Radiation Oncology. Fuller CD,van Dijk LV, Thompson RF, Scott JG, Ludmir EB, Thomas CR. Scientific Communication, Volume 108, Issue 2, P496-505, October 01, 2020. doi:https://doi.org/10.1016/j.ijrobp.2020.06.066
Human leukocyte antigen susceptibility map for SARS-CoV-2. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. J Virol. 2020 Apr 17. pii: JVI.00510-20. doi: 10.1128/JVI.00510-20.
Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Genome Med. 2020 Mar 30;12(1):33. doi: 10.1186/s13073-020-00729-2.
Real-world applications of deep convolutional neural networks in diagnostic cancer imaging. Elhalawani H, Yang P, Abazeed M, Shah C, Mohamed ASR, Thomas CR Jr, Fuller CD, Thompson RF. Chin Clin Oncol. 2020 Feb 1. pii: cco.2020.01.02. doi: 10.21037/cco.2020.01.02
neoepiscope improves neoepitope prediction with multivariant phasing. Wood MA, Nguyen A, Struck AJ, Ellrott K, Nellore A, Thompson RF. Bioinformatics. 2020 Feb 1;36(3):713-720. doi: 10.1093/bioinformatics/btz653.
In Regard to Wallner et al. Kang J, Thompson RF, Fuller CD, Camphausen KA, Gabriel PE, Thomas CR. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):217-218. doi: 10.1016/j.ijrobp.2019.10.044
Validity of Veterans Health Administration structured data to determine accurate smoking status. Golden SE, Hooker ER, Shull S, Howard M, Crothers K, Thompson RF, Slatore CG. Health Informatics J. 2019 Nov 7:1460458219882259. doi: 10.1177/1460458219882259.
Artificial Intelligence in Radiation Oncology. Deig CR, Kanwar A, Thompson RF. Hematol Oncol Clin North Am. 2019 Dec;33(6):1095-1104. doi: 10.1016/j.hoc.2019.08.003. Epub 2019 Sep 11
Tumor Mutation Burden-From Doubts to Concerns. Wood MA, Nellore A, Thompson RF. JAMA Oncol. 2019 Oct 24. doi: 10.1001/jamaoncol.2019.4138.
Clinical Documentation and Patient Care Using Artificial Intelligence in Radiation Oncology. Luh JY, Thompson RF, Lin S. J Am Coll Radiol. 2019 Sep;16(9 Pt B):1343-1346. doi: 10.1016/j.jacr.2019.05.044
Using Artificial Intelligence to Improve the Quality and Safety of Radiation Therapy. Pillai M, Adapa K, Das SK, Mazur L, Dooley J, Marks LB, Thompson RF, Chera BS. J Am Coll Radiol. 2019 Sep;16(9 Pt B):1267-1272. doi: 10.1016/j.jacr.2019.06.001.
Enhancing Career Paths for Tomorrow's Radiation Oncologists. Vapiwala N, Thomas CR Jr, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD Jr, Fuller CD, Thompson RF, Trister AD, Formenti SC,
The Potential and Pitfalls of Crowdsourced Algorithm Development in Radiation Oncology. Elhalawani H, Fuller CD, Thompson RF. JAMA Oncol. 2019 May 1;5(5):662-663. doi: 10.1001/jamaoncol.2019.0157.
Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation? Thompson RF, Valdes G, Fuller CD, Carpenter CM, Morin O, Aneja S, Lindsay WD, Aerts HJWL, Agrimson B, Deville C Jr, Rosenthal SA, Yu JB, Thomas CR Jr. Radiother Oncol. 2018 Dec;129(3):421-426. doi: 10.1016/j.radonc.2018.05.030.
Career Enrichment Opportunities at the Scientific Frontier in Radiation Oncology. Thompson RF, Fuller CD, Berman AT, Aneja S, Thomas CR Jr. JCO Clin Cancer Inform. 2019 Feb;3:1-4. doi: 10.1200/CCI.18.00126.